WO2023057880 - CRISPR/CAS9-BASED FUSION PROTEINS FOR MODULATING GENE EXPRESSION AND METHODS OF USE
National phase entry is expected:
Publication Number
WO/2023/057880
Publication Date
13.04.2023
International Application No.
PCT/IB2022/059433
International Filing Date
03.10.2022
Title **
[English]
CRISPR/CAS9-BASED FUSION PROTEINS FOR MODULATING GENE EXPRESSION AND METHODS OF USE
[French]
PROTÉINES DE FUSION À BASE DE CRISPR/CAS9 POUR MODULER L'EXPRESSION GÉNIQUE ET PROCÉDÉS D'UTILISATION
Applicants **
GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
GSK Medicines Research Centre
Gunnels Wood Road
Stevenage SG1 2NY, GB
Inventors
CHAKRABORTY, Syandan
Locust Street
Medford, Massachusetts 02155, US
CHOUDHURY, Rajarshi
1250 South Collegeville Road
Collegeville, Pennsylvania 19426, US
WALKER, William
1250 South Collegeville Road
Collegeville, Pennsylvania 19426, US
Priority Data
63/252,376
05.10.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1684 | |
| EPO | Filing, Examination | 8690 | |
| Japan | Filing | 602 | |
| South Korea | Filing | 576 | |
| USA | Filing, Examination | 4035 |
Total: 15587 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present disclosure generally relates to methods and compositions used for modulating or controlling gene expression involving sequence targeting, genome perturbation or gene-editing, that relate to Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and components thereof. In some embodiments, compositions comprising a catalytically inactive Cas9 (dCas9) fusion protein and methods for modulating expression of a gene of interest are disclosed.[French]
La présente invention concerne de manière générale des procédés et des compositions utilisés pour moduler ou réguler l'expression génique impliquant le ciblage de séquence, la perturbation du génome ou l'édition génique, qui se rapportent à des répétitions palindromiques courtes régulièrement espacées (CRISPR) et des composants corrrespondants. Dans certains modes de réalisation, l'invention concerne des compositions comprenant une protéine de fusion Cas9 inactive du point de vue catalytique(dCas9) et des procédés de modulation de l'expression d'un gène d'intérêt.